Evaluation of the Signa Excite 3.0 T MRI Excite for Detection and Characterization of Liver Lesions
NCT00527891 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 16
Last updated 2012-07-31
Summary
Primary Objective:
1\. To compare the efficacy of 1.5T vs. 3T T1 and T2-weighted MR images sequences for the detection and evaluation of liver lesions.
Conditions
Interventions
- PROCEDURE
-
Signa Excite 3.0 T MRI Scan
Signa Excite 3.0 T MRI scan within a two week period from the date of receiving standard 1.5 T MR of the liver area.
Sponsors & Collaborators
-
M.D. Anderson Cancer Center
lead OTHER
Principal Investigators
-
Janio Szklaruk, MD · M.D. Anderson Cancer Center
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-06-30
- Primary Completion
- 2007-09-30
Countries
- United States
Study Locations
More Related Trials
-
Magnetic Resonance Elastography and 2-Point Dixon MR Imaging Techniques in Diffuse Liver Disease
NCT00543777 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
PSMA PET/MRI or PSMA PET/CT for Evaluation of Liver Cancer
NCT04310540 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Role of FAPI PET/MR Combined With Gadoxetate Disodium in Assessing Hepatic Malignancies
NCT06287411 ·Status: RECRUITING
-
Imaging Response to Immunotherapy and Radiation Therapy in Patients With Liver Metastases
NCT03401814 ·Status: COMPLETED
-
DCE-MRI for Assessment of Response to TACE of HCC
NCT02878109 ·Status: COMPLETED
-
18F-FDGal PET/CT and PET/MRI in Patients With Hepatocellular Carcinoma
NCT05871892 ·Status: RECRUITING ·Phase: NA
-
Relationship Between 18FDG PET/MRI Patterns and ctDNA to Predict HCC Recurrence After Liver Transplantation
NCT03839706 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
The Role of PET/MRI in Predicting the Outcome of Definitive Chemoradiotherapy for Esophageal Cancer Patients
NCT05855278 ·Status: COMPLETED ·Phase: NA
-
Reproducibility and Repeatability of Multifunctional MRI Biomarkers of the Body
NCT02201797 ·Status: COMPLETED ·Phase: NA
-
68Ga-FAPI-FS PET/CT and PET/MR in Pancreatic Cancer
NCT05875753 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Early Therapy Response Monitoring in Melanoma Patients Using PET/MRI
NCT03132090 ·Status: UNKNOWN ·Phase: NA
-
Clinical Application of 68Ga-PSMA PET/MR for Diagnosis and Staging in Hepatocellular Carcinoma
NCT05006326 ·Status: UNKNOWN ·Phase: NA
-
4D Phase Contrast MR: Hypertrophy in Liver Cancer
NCT02618447 ·Status: TERMINATED ·Phase: NA
-
MRCP Diagnoses EHCC Better When Combined DWI
NCT01595217 ·Status: COMPLETED ·Phase: NA
-
Evaluation of PET/MRI in Patients With Pancreatic Adenocarcinoma
NCT02028377 ·Status: COMPLETED ·Phase: NA
-
Clinical Application of 18F-labeled RD2 PET/CT Imaging in the Diagnosis and Treatment of Small Liver Carcinoma
NCT05681234 ·Status: COMPLETED ·Phase: NA
-
MRE for Assessment of Histopathological Growth Patterns in Colorectal Liver Metastases
NCT06208397 ·Status: RECRUITING
-
MR/PET in the Evaluation of Patients With Esophageal Cancer
NCT02547610 ·Status: UNKNOWN
-
Clinical Application of 68Ga-FAPI PET Imaging in Detection of Ovarian Cancer Recurrence
NCT05856409 ·Status: RECRUITING
-
Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung
NCT01741597 ·Status: WITHDRAWN ·Phase: PHASE1
-
Magnetic Resonance Imaging (MRI) to Predict Outcomes of Pancreatic Ductal Adenocarcinoma (PDAC)
NCT04700488 ·Status: SUSPENDED ·Phase: NA
-
FAPI PET for Response Evaluation and Prognosis Prediction in Liver and Biliary Cancer Patients Treated With PD-1 Combination Therapy
NCT05662488 ·Status: UNKNOWN
-
Magnetic Resonance Imaging (MRI) in Motion
NCT02019199 ·Status: COMPLETED
-
The Value of Diffusion-weighted Imaging in Evaluating the Early Efficacy of Liver Metastasis in Colorectal Cancer
NCT03088163 ·Status: UNKNOWN ·Phase: NA
-
The Diagnostic Efficacy and Lesion Detection Advantages of 18F-FDG PET/CT and Enhanced MRI in Hepatic Malignancies
NCT06700564 ·Status: NOT_YET_RECRUITING